Payrits T, Ernst A, Ladits E, Pokorny H, Viragos I, Längle F
LK Wiener Neustadt, Chirurgie, Wiener Neustadt, Österreich.
Zentralbl Chir. 2011 Oct;136(5):431-5. doi: 10.1055/s-0031-1283739. Epub 2011 Oct 18.
The options for the conservative therapy of PAD, and also the achievable benefits are well documented in the S3-guidelines and the TASC-II guidelines. Upon vagal stimulation with a P-STIM device a significant extension of the pain-free and maximum walking distance could be noticed. As this fact continued beyond the end of the therapy, we may have found a new, conservative therapy option to manage PAD.
In a prospective single centre study we reviewed 31 patients with PAD (Fontaine stages II and III) who were treated by vagal stimulation with a P-STIM device. The following parameters were analysed: indication, duration of therapy, improvement of pain-free walking distance after therapy and complications.
31 patients received a vagal stimulation therapy for intermittent claudication in Fontaine stages II (97 %) and III (3 %). The duration of treatment averaged 6 weeks (minimum 2 weeks, maximum 9 weeks). 27 out of 30 patients were able to increase their pain-free walking distance up to a hundred-fold of the initial values. 3 patients could not give any information about increasing their walking distance in meters, but they reported about an obvious amelioration. All patients reported a continuing improvement after 4 weeks and after further 12 weeks, partly even about additional enhancement. Just 1 patient could not improve his walking-distance -after 3 periods of therapy. This was the only -patient with an isolated diabetic microangiopathy without stenosis or occlusions in the large vessels.
The considerable increase in pain-free walking distance after vagal stimulation therapy by P-STIM is appreciably better than those which were described for supervised exercise therapy or pharmacotherapy with Naftidrofuryl or Cilostazol. On the basis of these results we think that vagal stimulation by P-STIM might be a new option for treating intermittent claudication.
周围动脉疾病(PAD)保守治疗的选择及其可实现的益处已在S3指南和TASC-II指南中得到充分记录。使用P-STIM设备进行迷走神经刺激后,可观察到无痛行走距离和最大行走距离显著延长。由于这一现象在治疗结束后仍持续存在,我们可能发现了一种新的保守治疗方法来管理PAD。
在一项前瞻性单中心研究中,我们回顾了31例接受P-STIM设备迷走神经刺激治疗的PAD患者(Fontaine II期和III期)。分析了以下参数:适应症、治疗持续时间、治疗后无痛行走距离的改善情况以及并发症。
31例患者接受了迷走神经刺激治疗间歇性跛行,其中Fontaine II期患者占97%,III期患者占3%。治疗持续时间平均为6周(最短2周,最长9周)。30例患者中有27例能够将其无痛行走距离增加至初始值的百倍。3例患者无法提供关于行走距离增加的具体米数信息,但他们报告有明显改善。所有患者在4周后和再经过12周后均报告持续改善,部分患者甚至报告有进一步增强。只有1例患者在经过3个疗程的治疗后行走距离未改善。这是唯一一名患有孤立性糖尿病微血管病变且大血管无狭窄或闭塞的患者。
P-STIM迷走神经刺激治疗后无痛行走距离的显著增加明显优于监督运动疗法或使用萘呋胺酯或西洛他唑的药物治疗。基于这些结果,我们认为P-STIM迷走神经刺激可能是治疗间歇性跛行的一种新选择。